Taltz (ixekizumab) / Eli Lilly - LARVOL DELTA

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review. (PubMed, Mediterr J Rheumatol) - "Uveitis exposure-adjusted incidence rates per 100 patient years (EAIR/100PY) ranged between 0-4.5 for tumour necrosis factor inhibitors (TNFi), 0.5-3.9 for interleukin-17 inhibitors (IL-17i) and 0.8-3.3 for upadacitinib (UPA), as derived from available RCTs. Evidence from non-RCTs, reporting uveitis incidence rates per 100PY, ranged between 3.46-55.2 for etanercept, 1.38-15.7 for adalimumab, 1.82-25.9 for infliximab, 1.39-6.8 for golimumab, 0-9.4 for secukinumab and 0 for ixekizumab...IL-17i are identified as second line treatment option especially in uveitis refractory to TNFi. Finally, JAKi remain a promising alternative, with more evidence needed to further establish their so far proven efficacy."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Ocular Inflammation • Oncology • Ophthalmology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL17A

PRT19 A Product Theater for Taltz® (ixekizumab) and Zepbound® (tirzepatide) Injection including an Affordability Program for Eligible Taltz Patients Prescribed Zepbound (AAD 2026) - "Sponsored by: Lilly USA, LLC DESCRIPTION Join us for this Lilly event! Please see Full Prescribing Information for Zepbound including Boxed Warning and Medication Guide at the product theater or on www.zepbound.lilly.com"

Clinical

Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China. (PubMed, Inflamm Res) - "Predictors of biologic effectiveness differ by agent, supporting personalized treatment based on patient characteristics."

Journal • Dermatology • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis. (PubMed, JAMA Dermatol) - "Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Infection risk among psoriasis biologic-new users: a cohort study on the French National Health Data System. (PubMed, J Am Acad Dermatol) - "Biologics are associated with low overall infection risks. Among biologics, ustekinumab and IL-23 inhibitors show the lowest overall risk (time to the first inpatient/outpatient event)."

Journal • Dermatology • Immunology • Infectious Disease • Psoriasis • IL23A

The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis. (PubMed, Mediterr J Rheumatol) - "Conducting a search through PubMed/MEDLINE, Scopus, and Web of Science, using keywords and Medical Subject Headings (MeSH) terms such as "spondyloarthritis", "psoriatic arthritis", "IL-17A", "IL-17F", "IL-23", "IL-23 independent mechanisms", "dual inhibition", "pathogenesis", "gut-joint axis", "secukinumab", "ixekizumab", "bimekizumab", "sonelokimab", we select the relevant literature for this comprehensive pathophysiological narrative...Inhibiting both IL-17A and IL-17F signifies not only a significant therapeutic advancement but also a vital strategy towards overcoming the limitations of our current armamentarium in achieving deeper and more sustained remission in SpA. Future studies and long-term data will be essential in determining the position of dual IL-17A/F inhibitors within treatment guidelines."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A • IL23A

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We are the first to provide comparative evidence on the efficacy of newly investigated agents such as deucravacitinib, tildrakizumab, roflumilast and icotrokinra. In general, the IL-17 inhibitors (bimekizumab, ixekizumab, secukinumab, brodalumab) and IL-23 inhibitors (icotrokinra, guselkumab, tildrakizumab) were effective depending upon the outcome and time-point being considered. At 16 weeks, for PSSI-100, ixekizumab 150 mg at weeks 0, 2, 4, 8, and 12 ranked highest; at 16 weeks, for Sc-PGA 0/1 bimekizumab 320 mg every 4 weeks ranked highest; at 8 weeks, for PSSI-100 ixekizumab 80 mg every 2 weeks ranked highest; at 8 weeks, for Sc-PGA 0/1 secukinumab 300 mg at weeks 1, 2, 3 and then every 4 weeks ranked highest. Small-molecule therapies (apremilast, deucravacitinib, roflumilast) improved scalp psoriasis modestly. Our work would guide the design of future studies and clinical decision-making."

Clinical • Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study. (PubMed, RMD Open) - "IXE patients had significantly greater odds of achieving cDAPSA remission and VLDA, plus greater pain reduction versus the pooled IL-12/23i and IL-23i group, with significant improvements in BSA versus TNFi. Treatment persistence was similar among all b/tsDMARDs."

Clinical • HEOR • Journal • Observational data • Real-world evidence • Immunology • Inflammatory Arthritis • Oncology • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A

Real-World Efficacy and Safety of Ixekizumab from the Joint Psoriasis-Psoriatic Arthritis Clinic (PPAC). (PubMed, Clin Exp Dermatol) - "No serious adverse events were reported, and cardiovascular parameters remained stable. These findings support ixekizumab's strong efficacy and safety in routine clinical use, including patients with prior biologic exposure and complex disease, reinforcing its role as a cornerstone therapy."

Journal • Real-world evidence • Cardiovascular • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study). (PubMed, Front Med (Lausanne)) - "Exploratory subanalyses showed IXE persistence was not influenced by gender, smoking status, BMI, axSpA clinical form, CRP levels, HLA-B27 status, prior biological (b) or targeted synthetic (ts) DMARD (b/tsDMARD) or secukinumab. Most axSpA patients treated with IXE had long-standing, highly active disease involving multiple domains and prior multiple domains and prior b/tsDMARDs (b/tsDMARD) exposure. Despite this, half remained on IXE at 1 year with improved disease activity, highlighting its potential as a treatment option in daily practice."

Journal • Real-world evidence • Ankylosing Spondylitis • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • CRP

Herpes simplex risk during biologic treatment for erythrodermic psoriasis. (PubMed, World J Clin Cases) - "The recent case by Berjawi et al illustrates an atypical presentation of widespread herpes simplex virus-1 in a patient undergoing treatment with ixekizumab and topical corticosteroids, highlighting diagnostic uncertainty, cumulative immunosuppression, and therapeutic decision-making in severe psoriasis. This correspondence aims to emphasize the challenges of early herpes simplex virus recognition, discuss the potential but associative role of interleukin-17 inhibition in antiviral defence, and underscore the lack of clinical guidance regarding interruption and safe reintroduction of biologic therapy following viral clearance."

Journal • Cognitive Disorders • Dermatology • Dermatopathology • Herpes Simplex • Immunology • Infectious Disease • Psoriasis • IL17A

Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: Yale University | Recruiting ➔ Active, not recruiting

Enrollment closed

Outcomes in Bimekizumab Treated Psoriasis Patients With Prior IL-17 Inhibitor Failure. (PubMed, J Psoriasis Psoriatic Arthritis) - "Previous real-world studies have reported success with intra-class switching within the IL-17 inhibitor class, but data have been limited to secukinumab, ixekizumab, and brodalumab. Using retrospective data from cases selected for moderate-to-severe psoriasis who failed prior IL-17 therapy, we report our real-world experience using bimekizumab in 50 patients who failed a prior IL-17 inhibitor, in which 82% achieved an IGA 0/1. By demonstrating achievement of stringent benchmarks, such as IGA 0/1 and sPGAxBSA 100 in these selected patients, we challenge the conventional teaching of primary vs secondary non-responders class switching, and have found bimekizumab to be a viable option in those who have failed IL-17 inhibitor therapy in the past."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We identified 22 active comparators; "tofacitinib 10 mg twice daily" was ranked most efficacious in terms of 16 to 24-week mean change in NAPSI (SUCRA = 99.71%)-while "ixekizumab 160 mg at week 0 followed by 80 mg every 4 weeks" was ranked most efficacious (SUCRA = 95.67%) for proportion attaining PGA-f of 0 or 1 (i.e., outcome 2). Our analyses produced comparative evidence for the relative efficacy of monotherapies with various agents, including biologics and non-biologics. Our findings would guide clinical decision-making."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis

Model-Based Meta-Analysis of IL-17 A Inhibitors for Moderate-to-Severe Plaque Psoriasis: Establishing Exposure-Response Relationships to Inform Targeted Drug Development. (PubMed, Clin Rev Allergy Immunol) - "This study aimed to establish an exposure-response model for IL-17 A inhibitors to predict the clinical efficacy of novel agents based on in vitro potency and pharmacokinetic parameters, guiding the development of new IL-17 A-targeting therapies. A systematic literature search was conducted in PubMed, Cochrane Library, and Embase to identify randomized controlled trials of three FDA-approved IL-17 A inhibitors: secukinumab, ixekizumab, and bimekizumab. External validation showed high predictive accuracy for xeligekimab. A reference table was also constructed to estimate required doses based on IC50 and desired therapeutic targets, facilitating rational dose selection. Based on existing pharmacokinetic and clinical efficacy data of IL-17 A inhibitors, this study successfully developed a streamlined and accurate exposure-response model, offers a practical tool for efficacy prediction and dose optimization in the development of novel agents..."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • IL17A

Type IV pityriasis rubra pilaris treated with ixekizumab. (PubMed, An Bras Dermatol) - No abstract available

Journal

Recent advances in biologic therapies for ankylosing spondylitis: A 2024 update. (PubMed, Allergol Immunopathol (Madr)) - "This comprehensive analysis assesses therapeutic outcomes and adverse effects of TNFi, IL17i, and JAKi in AS care."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Oncology • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight (Eli Lilly Press Release) - "In a key secondary endpoint, use of Taltz and Zepbound delivered a 64% relative increase in the proportion of patients achieving ACR50 compared to Taltz alone (33.5% of patients vs. 20.4%, p<.05)...At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for superiority to Taltz monotherapy. TOGETHER-PsA is the first controlled study to evaluate an incretin therapy used with a PsA biologic...An the study, 31.7% of patients in the Taltz plus Zepbound treatment arm achieved a 50% improvement in PsA activity, based on American College of Rheumatology 50 (ACR50), and weight reduction of at least 10%, compared to 0.8% of patients on Taltz monotherapy, meeting the primary endpoint (p<.001)."

P3 data: top line • Obesity • Psoriatic Arthritis

Topline results from the ongoing TOGETHER-PsO trial, investigating the efficacy and safety of treating adults who have moderate-to-severe plaque psoriasis and obesity or overweight with concomitant Taltz and Zepbound compared to Taltz monotherapy, are also expected in the first half of 2026. (Eli Lilly Press Release)

P3 data: top line • Obesity • Psoriasis

Detailed 36-week results from the TOGETHER-PsA trial will be presented at an upcoming medical meeting and discussed with regulators. (Eli Lilly Press Release)

P3 data • Obesity • Psoriatic Arthritis

New-onset ulcerative colitis temporally associated with with ixekizumab in a psoriasis patient successfully treated with guselkunmab: A case report. (PubMed, Medicine (Baltimore)) - "Dermatologists closely monitor gastrointestinal symptoms in patients with psoriasis who are receiving ixekizumab to ensure safe medication use. Patients with ulcerative colitis and psoriasis may actively consider using guselkumab."

Journal • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pain • Psoriasis • Ulcerative Colitis • IL23A

Secukinumab compared to ixekizumab in biologic-naïve Chinese individuals afflicted with moderate-to-severe plaque psoriasis: A retrospective single-center analysis. (PubMed, Medicine (Baltimore)) - "The SB cohort experienced a higher incidence of adverse effects (P < .001, risk ratio = 0.52; 95% confidence interval = 0.37-0.73, I2 = 0%). In Chinese biologic-naïve patients with moderate-to-severe pPS, secukinumab may be associated with a superior response but a higher incidence of adverse effects compared with ixekizumab."

Clinical • Journal • Observational data • Retrospective data • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A

Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging. (PubMed, Rheumatol Ther) - P3 | "These findings support IXEQ4W as an effective treatment for Chinese patients with r-axSpA, irrespective of baseline MRI inflammation."

Journal • Ankylosing Spondylitis • Fatigue • Immunology • Inflammation • Inflammatory Arthritis • Pain • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Effectiveness and Continuous 2-Week Dosing of Ixekizumab in Practice: A Multicenter Study. (PubMed, J Dermatol) - "Higher body mass index (OR 1.11, 95% CI 1.01-1.23) and prior biologic therapy (OR 2.37, 95% CI 1.01-5.58) were significant predictors; smoking, alcohol, baseline severity, and nail involvement were not. Ixekizumab showed durable effectiveness, and sustained Q2W dosing was a practical option for patients with higher BMI or prior biologic exposure."

Clinical • Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A